Abstract 56P
Background
Hippocampus is associated with formation and storage of new memory and irradiation of same during whole brain radiotherapy in brain metastases leads to decline in the neurocognitive function. Recent advancements in radiation delivery in form of IMRT, Hippocampal avoidance has been made possible. We analyze feasibility of hippocampal sparing and associated neurocognitive and dosimetric assessment.
Methods
Between June 2016 to December 2017, 125 patients diagnosed radiologically and clinically with brain metastases were included in the study. Mini Mental State Examination (MMSE) and quality of life assessment with EORTC BN20 questionnaire were assessed along with dosimetry. Patients were assessed at baseline and followed by at 1, 3 and 6 months respectively. Factors were compared with the historical group with relation to quality of life especially neurocognitive functioning. Wilcoxon test for multiple comparisons was calculated to detect significant differences in global QoL scores.
Results
Median age of accrued 125 patients was 48 years. Median D100% and Dmax to contralateral hippocampus was 7.1Gy and 16.7Gy. With IMRT, the doses to other critical structures were reduced. Patients treated with IMRT were found to have achieved desired dose constraints to hippocampus. Assessment of neurocognitive function between two groups, there was no difference at 1 month after treatment, however, difference was seen at 3 and 6 months favouring hippocampal avoidance. No difference noted in other aspects of quality of life between two groups. No severe toxicities (Grade 3 and 4) were noted in either group. Median survival in the HA-WBRT arm was found to be 10.1 months.
Conclusions
Conformal avoidance of hippocampus during WBRT is associated with improved neurocognitive function and quality of life. IMRT has found to provide better dosimetric outcomes in HA-WBRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract